Susceptibility patterns of Candida species recovered from Canadian intensive care units
| Autor: | Coleman Rotstein, Thomas E. Stewart, Daren K. Heyland, Michel Laverdière, C. Restieri, Annie-Claude Labbé, Sheldon Madger |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Canada Antifungal Agents Microbial Sensitivity Tests Critical Care and Intensive Care Medicine Candida parapsilosis Microbiology Candida tropicalis Drug Resistance Fungal Candida krusei medicine Prevalence Humans Candida albicans Cells Cultured Candida Cross Infection biology Candida glabrata business.industry Micafungin Candidiasis Middle Aged bacterial infections and mycoses biology.organism_classification Intensive Care Units Aminocandin Anidulafungin Female business medicine.drug |
| Zdroj: | Journal of critical care. 22(3) |
| ISSN: | 0883-9441 |
| Popis: | Objective: The objective of this study was to determine the speciation and susceptibility patterns of Candida species recovered from Canadian intensive care units (ICUs) during a 1-day point-prevalence study on fungal colonization/infection in Canadian ICUs. Methods and Setting: Blood, urine, respiratory tract, rectal, and wound fungal cultures were performed for 357 patients present at any time during a single-day 24-hour period in 35 Canadian ICUs. Comparative in vitro activities of amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole, micafungin, anidulafungin, and aminocandin were determined. Results: Four hundred fifteen yeasts (409 Candida species and 6 non-Candida yeasts) were recovered. Almost 50% of the patients were found to have positive respiratory tract or rectal cultures. Candida albicans accounted for 72% of the Candida species isolated, followed by Candida glabrata (16%), Candida tropicalis (5%), Candida parapsilosis (3%), Candida krusei (2%), and other Candida species or nonspeciated isolates (2%). Minimum inhibitory concentrations (milligrams per liter) at which 90% of the strains were inhibited were 0.06 for micafungin as well as anidulafungin, 0.12 for voriconazole, 0.25 for itraconazole, posaconazole, as well as aminocandin, 1 for amphotericin B, and 4 for fluconazole. Only 4% of the isolates were resistant to fluconazole and/or itraconazole. Conclusions: Candida albicans is the predominant species colonizing Canadian ICU patients. Overall, the triazoles, both older and new compounds, and the echinocandins have excellent in vitro antifungal activities against Candida species recovered from Canadian ICUs patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect